心跳停止後症候群：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國PCAS市場預計將從2025年的3,600萬美元成長到2035年的6,500萬美元。
• 推動市場成長的因素如下：
• 標靶體溫管理和重症監護方面的進展
• 神經保護和器官保護治療的研究日益增多
• 未來的成長取決於能夠改善長期神經系統預後和存活率的治療方法。

心跳停止後症候群概述

心跳停止後症候群是指心跳停止後復甦成功後發生的複雜疾病，包括腦損傷、心臟功能障礙和全身性發炎反應。心跳停止後存活患者的預後很大程度上取決於如何管理這段脆弱時期。目前的治療方法採用協調一致的方法，同時關注多個系統，包括嚴格控制血壓、血氧飽和度和血糖值，以及進行體溫管理，目的是復甦後有限的時間內抑制進一步的腦損傷。體溫管理策略本身也發生了顯著變化，指南已從嚴格的深度治療性降溫轉變為更廣泛、更個體化的方法，強調預防發燒以及針對特定部位的低溫治療。這反映了臨床試驗的積累，即積極的降溫並不總是優於謹慎地避免發燒。確定患者的神經系統預後仍然是治療中最具挑戰性的方面之一，需要進行延遲的、多方面的評估，而不是依賴單一的早期檢查。

主要亮點

• 在德國，與心跳停止後症候群（PCAS）相關的可治療的院內心臟驟停（IHCA）病例數預計將從2025年的7,451 例增加到2035年的7,640 例。
• PCAS 是一種危及生命的疾病，其特徵是心跳停止後發生的神經損傷、心肌功能障礙和全身缺血再灌注損傷。
• 儘管重症監護技術取得了進步，但死亡率和神經系統併發症仍然很高。
• 目前，改善神經功能恢復和提高存活率的治療方法仍存在巨大的未滿足需求。

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

提及公司

• Invero Pharma, Inc.

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章 未滿足的需求與目標產品分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Post-Cardiac Arrest Syndrome Market Outlook

Thelansis's "Post-Cardiac Arrest Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Post-Cardiac Arrest Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Post-Cardiac Arrest Syndrome Overview

Post-cardiac arrest syndrome describes the combination of brain injury, heart dysfunction, and body-wide inflammatory response that follows successful resuscitation after cardiac arrest, and outcomes for patients who survive the initial event are shaped heavily by how this vulnerable period afterward is managed. Care today follows a coordinated bundle addressing multiple systems at once, including careful control of blood pressure, oxygen levels, and blood sugar, alongside temperature management aimed at limiting further brain injury during the window following resuscitation. That temperature strategy has itself evolved meaningfully, with guidance moving away from a strict requirement for deep therapeutic cooling toward a broader, more individualized approach that emphasizes preventing fever as much as targeting a specific low temperature, reflecting accumulating trial evidence that aggressive cooling does not universally outperform careful fever avoidance. Determining a patient's neurological prognosis remains one of the hardest aspects of care, requiring a delayed, multimodal assessment rather than reliance on any single early test.

Key Highlights

• In Germany, treatable in-hospital cardiac arrest (IHCA) cases associated with Post-Cardiac Arrest Syndrome (PCAS) are projected to increase from 7,451 in 2025 to 7,640 by 2035.
• PCAS is a life-threatening condition characterized by neurological injury, myocardial dysfunction, and systemic ischemia-reperfusion injury following cardiac arrest.
• Despite advances in critical care, mortality and neurological disability remain high.
• Significant unmet need remains for therapies that improve neurological recovery and survival.

Market Overview

• The France PCAS market is projected to grow from $36M in 2025 to $65M by 2035.
• Market growth is driven by:
• Advances in targeted temperature management and critical care therapies
• Increasing research into neuroprotective and organ-protective treatments
• Future growth will depend on therapies that improve long-term neurological outcomes and survival.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Invero Pharma, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)